Helping the world breathe easier

Planned Products and Revenue Sources

AeroCell™ disposable drug cartridge. For use with all products. Source of  continuous revenue.

Mass immunization nebulizer drug delivery system. Device sales and AeroCell™ revenue.

Aerocurrent™ next-generation, point–of-care therapy system for established markets. Device sales, AeroCell™ and disposable mask revenue.

Licensing revenue from pharmaceutical companies for specialty drug delivery.

The product line centers on the proprietary AeroCell™ disposable drug cartridge for use with all AerovectRx products.  The AeroCell™ provides for highly efficient and effective inhaled delivery of drugs, vaccines and therapeutics and a continuing revenue stream. Our planned initial product is the multiuse, mass inoculation system – the first use of a multiple-use mass immunization nebulizer drug delivery system. The next generation Aerocurrent™ system is designed for use in the point-of-care market to deliver drugs, vaccines and therapeutics including high-end biologics in established markets. Revenue for the company is primarily derived from sales of a handheld device, AeroCell™ disposables and single-patient-use masks.

The Markets

Our technology has numerous applications for novel inhaled drug delivery, including inhaled insulin; respiratory therapies for asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and cystic fibrosis.  Additional applications include biodefense, outbreak readiness and preparation for avian flu, anthrax, smallpox and other emerging threats.

CAUTION - Investigational devices. Limited by federal law to investigational use. The availability of any product in the U.S. developed from these technologies is dependent on FDA marketing approval. Global market availability is dependent on additional regulatory approvals.